跳至主要内容
临床试验/NCT02805283
NCT02805283已完成不适用

Direct to Patient Survey to Examine Treatment Satisfaction and Experience With Dapagliflozin Compared to Sulfonylureas

AstraZeneca1 个研究点 分布在 1 个国家目标入组 653 人开始时间: 2016年6月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
653
试验地点
1
主要终点
Condition-specific treatment satisfaction

研究概览

简要总结

The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus

详细描述

This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

性别
All
接受健康志愿者

入选标准

  • At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification.
  • Evidence of T2D diagnosis.
  • Age ≥18 as of the drug index date.
  • 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date.
  • Self-reported T2D diagnosis during the patient interview.

排除标准

  • Patients with evidence of type 1 diabetes mellitus and unknown type
  • Patients who are pregnant

结局指标

主要结局

Condition-specific treatment satisfaction

时间窗: 2 weeks

Condition-specific treatment satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)

次要结局

  • Hypoglycemia Fear Survey(4 weeks)
  • Medical Outcomes Study (MOS) Short Form Health Survey SF-12 or SF-36(4 weeks)
  • Morisky Medication Adherence Scale(1 month)
  • Self-reported body weight(1 month)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验